Summary: Recent research examines psychedelic-assisted experiences as a potential treatment for mental health conditions. A new analysis finds that more mystical and insightful “trips” are associated with lasting reductions in anxiety and depression symptoms.
Source: Ohio State University
A new study suggests that psychedelic experiences marked by strong mystical and insightful qualities are linked to sustained improvements in anxiety and depression.
Researchers applied machine learning methods to survey data from nearly 1,000 people who reported prior non-clinical psychedelic experiences. The analysis indicates that participants who rated their experiences highest on measures of mysticalness and psychological insight consistently reported larger and longer-lasting reductions in anxiety and depression symptoms.
The study also found that challenging or difficult experiences—those that feel frightening or destabilizing—can still lead to positive mental health outcomes, particularly when they occur alongside mystical or insight-rich experiences. This finding may help clinicians and therapists support participants in clinical trials of psychedelic-assisted therapies.
“Sometimes a difficult moment comes because the experience itself is intensely mystical and insightful, and that intensity can feel challenging,” said senior author Alan Davis, assistant professor and director of the Center for Psychedelic Drug Research and Education in The Ohio State University College of Social Work.
“In clinical settings, teams try to create a safe, supportive environment. When challenges arise, it’s important to recognize that those experiences can still be associated with positive outcomes.”
The findings were published online in the Journal of Affective Disorders.
This is the first study to define reproducible subtypes of the subjective psychedelic experience and link those subtypes to mental health outcomes. The research used responses from an anonymous online survey led by Davis, in which participants reported a moderate to strong psychedelic experience and any resulting changes in symptoms of anxiety and depression, regardless of their initial symptom levels.
A total of 985 respondents provided information about the substance they used and completed validated questionnaires about whether their experience felt mystical (characterized by a sense of pure awareness, profound positive mood, or transcendence of time and space), psychologically insightful (bringing acute clarity about memories, emotions, relationships, behaviors, or beliefs), or challenging.
Survey outcomes included self-reported levels of depression and anxiety, satisfaction with life, and psychological flexibility—the capacity to act according to one’s values despite internal or external experiences—reported for the period before and after the psychedelic experience.
Participants had used a range of psychedelics, including psilocybin (magic mushrooms), LSD, ayahuasca, mescaline, peyote, and 5-MeO-DMT (the natural psychedelic found in Colorado River toad venom). Respondents also recalled the approximate dose of the primary substance they used.
Cluster analysis of the data revealed three distinct subtypes of psychedelic experiences:
- High scoring: strong mystical and insightful ratings with moderate challenge scores.
- Low scoring: low to moderate mystical and insight ratings with low challenge scores.
- Positive scoring: high mystical and insightful ratings with low challenge scores.
“Participants who reported the most mystical and insightful experiences combined with low levels of challenge showed the greatest benefit—greater remission of anxiety and depression symptoms and longer-term improvements in life satisfaction and wellbeing,” said first author Aki Nikolaidis, a research scientist affiliated with Ohio State’s Center for Psychedelic Drug Research and Education and the Child Mind Institute’s Center for the Developing Brain.
When the team restricted analyses to users of psilocybin and LSD, the same three subtypes appeared and related to the same mental health outcomes, including sustained benefits even after challenging experiences. This consistency across substances highlights the central role of subjective experience in psychedelic effects.
“Finding subtypes that occur regardless of which psychedelic was used helps explain why subjective qualities of the experience matter,” Nikolaidis said. “Replicating these associations shows the strong link between what people experience subjectively and the potential for beneficial mental health outcomes.”
Additional trends emerged: the positive scoring group—those with high mystical and insight scores and low challenge—tended to be younger than participants in the other groups. Individuals reporting the most challenging experiences were more likely to have taken larger doses. The low scoring group started with lower psychological flexibility and lower anxiety and depression symptoms before their psychedelic experience and showed smaller improvements in symptoms and life satisfaction afterward.
Davis noted he will monitor whether these experience subtypes also appear in clinical trials, such as ongoing psilocybin-assisted therapy research at Ohio State evaluating treatments for post-traumatic stress disorder in military veterans.
“A next step is to explore other outcomes these subtypes may predict,” he said. “That could include functional measures of quality of life, wellbeing, relationships, or a clearer sense of life purpose.”
Funding: This work was supported by the Brain and Behavior Research Foundation, the National Institute of Mental Health, the Center for Psychedelic Drug Research and Education (CPDRE), the Steven & Alexandra Cohen Foundation, and private donors.
Additional co-authors include Rafaelle Lancelotta of Ohio State, and Natalie Gukasyan, Roland Griffiths and Frederick Barrett of the Center for Psychedelic & Consciousness Research at Johns Hopkins School of Medicine, where Davis is also an affiliate.
About this psychedelics, mental health, and psychopharmacology research news
Author: Emily Caldwell
Source: Ohio State University
Contact: Emily Caldwell – Ohio State University
Image: The image is in the public domain
Original Research: Open access. Title: “Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms” by Alan Davis et al., Journal of Affective Disorders. DOI referenced in the original publication.
Abstract
Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms
Background
Subjective qualities of psychedelic experiences appear to play a key role in the long-term effects on mental health. Although clinicians and researchers often emphasize the importance of the subjective experience, a systematic description of distinct experience subtypes and how they relate to outcomes has been lacking.
Methods
This study used machine learning cluster analysis to identify three reproducible subtypes of psychedelic experience from a large cross-sectional sample (n = 985).
Results
The identified subtypes were consistently associated with reductions in anxiety and depression and with broader markers of psychological wellbeing. The structure and outcome relationships for these subtypes were reproducible across multiple psychedelic substances.
Limitations
Data were collected via retrospective self-report, limiting the ability to infer causation between baseline characteristics, subjective experience qualities, and subsequent outcomes.
Conclusions
The analysis indicates that psychedelic experiences linked to lasting mental health benefits can be characterized by reproducible and predictable subjective subtypes. These subtypes differ in baseline demographics, initial mental health status, drug type, and dose. The findings suggest that enhancing mystical and personal insight experiences may be a promising strategy to maximize benefits in clinical approaches that use psychedelic-assisted treatment.